Drugs and biologics that have shown positive results in clinical research to slow or reverse normal aging processes
| Family | Indication | Leading agent | Study type | Reference |
|---|---|---|---|---|
| Longevity candidates | Longevity | Vitamin D | Observational | [34, 36] |
| Metformin | Observational | [40] | ||
| Mesenchymal stem cells | Locomotion frailty | Lomecel-B | RCT (phase 2) | [47] |
| Facial rejuvenation | SVF | RCT | [54] | |
| Senolytics drugs | Cognitive decline | D + Q | OL (phase 1) | [58] |
| Sirtuin activators | Aging frailty | Resveratrol | RCT (phase 2) | [61] |
| NAD+ precursors | Physical performance | NRS | RCT | [65] |
SVF: stromal vascular fraction; D + Q: dasatinib and quercetin; NRS: nicotinamide riboside supplements; OL: open-label